Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer
HER2-low expression is associated with hormone receptor (HR) expression in HR-positive breast cancer. We aimed to evaluate its association with androgen receptor (AR) among 196 patients with metastatic triple-negative breast cancer (mTNBC). Central determination of AR showed significant enrichment in HER2-low compared with HER2-0 mTNBC (mean: 33.7% vs. 21.4%, p = 0.038), whereas no significant immunological differences were observed. HER2-low/AR-positive patients trended towards longer overall survival, highlighting the potential relevance of these biomarkers.
Authors
- Xiao‐Hua Zhou (ORCID: https://orcid.org/0000-0001-7935-1222)
- Melissa E. Hughes (ORCID: https://orcid.org/0000-0001-6190-9101)
- Jaeyoon Cha (ORCID: https://orcid.org/0000-0003-1436-369X)
- Bojana Jovanović (ORCID: https://orcid.org/0000-0002-6971-4525)
- Molly K. DiLullo (ORCID: https://orcid.org/0009-0005-1036-796X)
- Xiangying Chu (ORCID: https://orcid.org/0009-0000-3474-3804)
- Eileen Wrabel
- Rinath M. Jeselsohn (ORCID: https://orcid.org/0000-0001-7996-7529)
- Douglas Russo (ORCID: https://orcid.org/0000-0002-2502-1540)
- Jamie Carter
- S. Goel
- Paolo Tarantino (ORCID: https://orcid.org/0000-0001-8686-0228)
- Nabihah Tayob
- Yisang Serenity Chen
- Busem Binboga Kurt
- Nancy U. Lin
- Sara M. Tolaney
- Stuart J. Schnitt
- Elizabeth A. Mittendorf
- Tianyu Li
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Loxo Oncology at Lilly (United States) (US)
- Dana-Farber/Harvard Cancer Center (US)
- Dana-Farber Brigham Cancer Center (US)
Publication Details
- Journal
- npj Breast Cancer
- Published
- 2026-02-13
- DOI
- https://doi.org/10.1038/s41523-026-00913-4
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Breast Cancer Research Foundation
- METAvivor
- Terri Brodeur Breast Cancer Foundation